Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFTR | P13569 | 1/20 | 0.41 |
| ▸ | ADCY10 | Q96PN6 | 2/20 | 0.39 |
| ▸ | SCN10A | Q9Y5Y9 | 3/20 | 0.36 |
| ▸ | CASP1 | P29466 | 1/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.35 |
| ▸ | SCN2A | Q99250 | 2/20 | 0.35 |
| ▸ | SCN3A | Q9NY46 | 2/20 | 0.35 |
| ▸ | SCN1A | P35498 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.33 |
| ▸ | PLK1 | P53350 | 1/20 | 0.33 |
| ▸ | JAK2 | O60674 | 1/20 | 0.33 |
| ▸ | IKBKB | O14920 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31656690 | 1.00 | CFTR (0.41) | CFTRADCY10SCN10ACASP1SCN9A | |
| SCHEMBL31330598 | 0.83 | ADCY10 (0.40) | CFTRADCY10SCN10ACASP1SCN9A | |
| SCHEMBL25203400 | 0.83 | ADCY10 (0.40) | CFTRADCY10SCN10ACASP1SCN9A | |
| SCHEMBL536169 | 0.81 | KDM4E (0.50) | CASP1KDM4ESMN1; SMN2GAA | |
| SCHEMBL25359700 | 0.81 | ADCY10 (0.39) | ADCY10SCN10ACASP1SCN9ASCN2A | |
| SCHEMBL535620 | 0.80 | KDM4E (0.39) | CASP1KDM4EUSP2HTTSMN1; SMN2 | |
| SCHEMBL31330687 | 0.80 | KDM4E (0.39) | CASP1KDM4EUSP2HTTSMN1; SMN2 | |
| SCHEMBL31330617 | 0.79 | RAB9A (0.49) | KMT2AKDM4EHTTSMN1; SMN2MEN1 | |
| SCHEMBL31330675 | 0.77 | CFTR (0.40) | CFTRSMN1; SMN2 | |
| SCHEMBL25359313 | 0.74 | CFTR (0.44) | CFTRADCY10SCN10ASCN9ASCN2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4720061-A1 | TREM2 AGONISTS | F. Hoffmann-La Roche AG (CH) | 2026-04-08 | — | — | EP | disclosed |
| EP-4720062-A1 | PYRIDO[3,4-D]PYRIMIDIN-4-ONE AND PYRIMIDO[5,4-D]PYRIMIDIN-4-ONE DERIVATIVES AS TREM2 AGONISTS FOR THE TREATMENT OF PARKINSON'S DISEASE | F. Hoffmann-La Roche AG (CH) | 2026-04-08 | — | — | EP | disclosed |
| US-20260035375-A1 | TREM2 MODULATORS | MUNA THERAPEUTICS APS (DK) | 2026-02-05 | — | — | US | disclosed |
| US-12459953-B2 | TREM2 modulators | MUNA THERAPEUTICS APS (DK) | 2025-11-04 | — | — | US | disclosed |
| US-12459952-B2 | TREM2 modulators | MUNA THERAPEUTICS APS (DK) | 2025-11-04 | — | — | US | disclosed |
| US-20250223293-A1 | TREM2 MODULATORS | MUNA THERAPEUTICS APS (DK) | 2025-07-10 | — | — | US | disclosed |
| US-20250223294-A1 | TREM2 MODULATORS | MUNA THERAPEUTICS APS (DK) | 2025-07-10 | — | — | US | disclosed |
| WO-2024246019-A1 | PYRIDO[3,4-D]PYRIMIDIN-4-ONE AND PYRIMIDO[5,4-D]PYRIMIDIN-4-ONE DERIVATIVES AS TREM2 AGONISTS FOR THE TREATMENT OF PARKINSON'S DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2024-12-05 | — | — | WO | disclosed |
| WO-2024246018-A1 | TREM2 AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2024-12-05 | — | — | WO | disclosed |
| WO-2023159155-A1 | INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) AND USES THEREOF | PIVALENT THERAPEUTICS, INC. (US) | 2023-08-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12459953-B2 | TREM2 modulators | FCER2, MERTK, FCGR1A | CFTR 1857/4885ADCY10 3334/4885SCN10A 2377/4885 |
| US-20250223293-A1 | TREM2 MODULATORS | FCER2, MERTK, FCGR1A | CFTR 1857/4885ADCY10 3334/4885SCN10A 2377/4885 |
| US-12459952-B2 | TREM2 modulators | FCER2, MERTK, FCGR1A | CFTR 1857/4885ADCY10 3334/4885SCN10A 2377/4885 |
| US-20260035375-A1 | TREM2 MODULATORS | MSR1, CSF1R, CX3CR1 | CFTR 1809/4885ADCY10 1947/4885SCN10A 1270/4885 |
| US-20250223294-A1 | TREM2 MODULATORS | FCER2, MERTK, FCGR1A | CFTR 1857/4885ADCY10 3334/4885SCN10A 2377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.